USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: Houston Biotechnology, Inc.
City: The Woodlands
State: TX
Zip+4: 77381
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $599,255.00 11
SBIR Phase II $500,000.00 1

Award List:

BIOFLAVONOID METABOLITES AND TUMOR CELL INHIBITION

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The objective of this project is to synthesize compounds (chalcones and their analogs) related to a natural product (methyl p-hydroxyphenyllactate or mehpla) that may be useful as antitumor agents. studies have demonstrated that normal and malignant cells contain high-affinity binding sites for… More

AN OCULAR NEUROTROPHIC FACTOR TO TREAT GLAUCOMA

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas L Wallace
Award Amount: $49,637.00

MONOCLONAL ANTIBODY AGAINST 2'-DEOXYCYTIDINE, A PUTATIVE INTRACELLULAR MESSENGER

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas L. Wallace , Principal Investigator
Award Amount: $50,000.00
Abstract:
2'-deoxycytidine (dcyt) is hypothesized to act as an intracellular messenger of trophic factor signal transduction and a mediator of neuronal death by a mechanismthat does not involve dna synthesis or repair. the long term objective of this work is to determine the nervous system role of dcyt in… More

PVR\AN IMMUNOPHARMACOLOGICAL APPROACH TO TREATMENT

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kelleher, Peter J , Principal Investigator
Award Amount: $50,000.00
Abstract:
Proliferative vitreoretinopathy (pvr) is a potentially blinding disease caused by the migration into and subsequent proliferation of retinal pigmented epithelial cells (rpe), glial cells, fibroblasts and macrophages in the vitreous cavity. this invasion of the vitreous can result from disease or… More

GLAUCOMA FILTERING SURGERY: IMPROVED BY DRUG CONJUGATES

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kelleher, Peter J , Principal Investigator
Award Amount: $50,000.00
Abstract:
Filtering surgery, when successful, is an effective method to reduce intraocular pressure and visual field loss in glaucoma patients. the creation of a surgical filter in these patients provides an artificial route for aqueous drainage that bypass the trabecular meshwork. however, this procedure is… More

IOL-IMMOBILIZED IMMUNOTOXINS TO PREVENT SECONDARY CATARA

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kelleher, Peter J , Principal Investigator
Award Amount: $49,618.00
Abstract:
Secondary cataract results from the proliferation of residual lens epithelial cells following extracapsular cataract surgery. growth of these cells on the posterior capsule surface can eventually cause a clouding or distortion of the capsule and hence reduce vision. an agent that specifically… More

AN OCULAR NEUROTROPHIC FACTOR TO TREAT GLAUCOMA

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Thomas L Wallace
Award Amount: $500,000.00
Abstract:
The ciliary ganglion innervates several important eye tissues, including the ciliary muscle and body, and has been shown to regulate aqueous outflow and accommodation. the eye disorders, glaucoma and presbyopia, may involve the ciliary ganglion through its regulation of aqueous outflow and visual… More

IMMUNOTOXIN TREATMENT OF BLEPHAROSPASM AND STRAABISMUS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas L Wallace
Award Amount: $50,000.00
Abstract:
Blepharospasm and strabismus are chronic, debilitating, ocular spastic disorders caused by uncontrolled or balanced muscle contraction. the long-term objective of this work is to create a therapeutic agent that will ablate cholinergic neurons responsible for the muscle contraction in blepharospasm… More

CONSTRUCTION OF CHICKEN X MOUSE HYBRIDOMAS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter J Kelleher
Award Amount: $50,000.00
Abstract:
We will construct chicken kh mouse hybridoma cell lines secreting chicken mabs to selected antigens. a primary advantage in the construction of these hybridomas is the genetic differences between chickens and mammals which increases the chance of producing antibodies against highly conserved regions… More

DISULFIDE LINKAGE OF IMMUNOTOXINS BY IGG OLIGOSACCHARIDE

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter J Kelleher
Award Amount: $50,000.00
Abstract:
The preparation of immunotoxins composed of ricin a and immunoglobulins has classically been performed with heterobifunctional crosslinkers such as n-succinimidyl 3-(2-pyridyldithio) propionate (spdp). these crosslinkers react with the epsilon-amino groups of lysine on the igg molecule and the… More

Novel Treatment for Intractable Pain

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Thomas L. Wallace
Award Amount: $50,000.00
Abstract:
Intractable pain is chronic pain for which there is little or no effective therapy. We will create a therapeutic agent that will chemically ablate peripheral pain nerves involved in intractable pain and, thereby, treat painful human disorders in which the pain does not serve a useful purpose. The… More

Drug Assocated Polymer Implants for Ocular Indications

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Peter Kelleher
Award Amount: $100,000.00
Abstract:
We will test, in rabbits, implants that slowly release antiproliferative drugs that could improve tocular surgery. In one case the objective is to inhibit the growth of residual lens epithelium aftersurgery, and in another to prevent the sealing up of the drainage pathway by fibroblast activity… More